Treatment of skin scars
Topical treatment using combinations of drugs such as nintedanib and propranolol, or propranolol and tranilast, has solved the problem of poor efficacy in treating skin scars in existing technologies, and has achieved effective inhibition of keloids and hypertrophic scars.
Patent Information
- Application Number
- CN202580027899.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-16
- Filing Date
- 2025-04-15
- Publication Date
- 2026-11-17
AI Technical Summary
Existing treatments for skin scars, especially keloids and hypertrophic scars, have limited effectiveness, lack internationally recognized care standards, and have unclear etiologies and pathologies.
Drug combinations such as nintedanib and propranolol, propranolol and tranilast, fosinopril and tranilast are used to inhibit the proliferation and fibrosis of keloid cells through local treatment or injection.
It significantly inhibited the proliferation and fibrosis of keloid cells, improved treatment efficacy, and provided a more effective treatment option for skin scars.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the treatment of human skin scars, such as keloids, hypertrophic or atrophic scars, etc. Background Technology
[0002] Skin scars can occur when normal skin tissue is replaced by fibrotic tissue during the healing process, and can appear after trauma, surgery, infection, and / or inflammation. Examples of skin scars may include, but are not limited to, keloid scars, hypertrophic scars, atrophic scars, and acne scars.
[0003] Keloid scars are abnormal overgrowths of fibrous tissue at the site of a healing wound. A keloid scar may appear as a raised area relative to the surrounding skin and tends to extend further than the initial location of the wound. Besides the obvious aesthetic problems, keloid scars can be associated with symptoms such as itching and pain. Hypertrophic scars, on the other hand, are often contained within the injured area and may fade over time.
[0004] Public data suggests that people with darker skin are more prone to keloids. However, people with albinism in Africa show a similar prevalence rate to those without albinism, indicating that factors other than skin pigmentation are also involved in the pathophysiology of keloid development.
[0005] Currently, there is no clearly known cause or pathology for the development of keloids. Therefore, known treatments for keloid scars, such as excision, cryosurgery, triamcinolone acetonide (TAC), 5-fluorouracil (5FU), silicone gel, and pressure therapy, have achieved limited success. There are no internationally recognized standards of care for this condition.
[0006] Purpose of the invention
[0007] The preferred embodiments of the present invention aim to at least to some extent treat, prevent, or limit the development of human skin scars (such as keloids or hypertrophic scars).
[0008] definition
[0009] The terms “comprising” or “having”, when used in connection with one or more features in this document, should not be considered as excluding the selection of additional, unmentioned features. The same applies to derived terms such as “including” and “having”.
[0010] The pharmaceutically active agents mentioned in this document include their pharmaceutically active salts. Where the weight of the agent is given, the relevant figure should be considered an adjustment for its applicability to the salt. For example, reference to fosinopril should be understood to also include pharmaceutically acceptable salt forms of fosinopril, and in this case, any weight expressed in the claims should be understood to represent the additional mass of the salt. For example, 332.3 g (1 mol) of propranolol hydrochloride can be considered equivalent to 259.3 g (1 mol) of propranolol. As another example, 563.7 g (1 mol) of fosinopril can be considered substantially equivalent to 585.6 g (1 mol) of fosinopril sodium.
[0011] The term "FTU" stands for "fingertip unit," or in other words, the amount of medication that an adult fingertip typically carries when fully loaded with the medication. One FTU contains approximately 450 mg to 550 mg of medication, and preferably approximately 500 mg of medication. Summary of the Invention
[0012] The first aspect – medicine
[0013] According to one aspect of the present invention, a medicament for treating skin scars is provided, comprising any one of the following active substances:
[0014] a) Nintedanib and Propranolol;
[0015] b) Propranolol and Tranilast;
[0016] c) Nydanibu and Fosinopril;
[0017] d) Forsimpley and Trinister;
[0018] e) Verapamil and propranolol; or
[0019] f) Verapamil and Nidanibu.
[0020] Optionally, the drug is used for local treatment or local injection at or near the scar.
[0021] Optionally, the active substances have the following molar ratios:
[0022] a) 1 mole of nintedanib and 27-33 moles of propranolol;
[0023] b) 1 mole of propranolol and 4-6 moles of tranilast;
[0024] c) 1 mole of nintedanib and 36-44 moles of fosinopril;
[0025] d) 1 mole of fosinopril and 1.8-2.2 moles of tranilast;
[0026] e) 1 mole of verapamil and 1.1–1.5 moles of propranolol; or
[0027] f) 1 mole of verapamil and 0.05–0.08 moles of nintedanib.
[0028] Optionally, the active substances have the following molar ratios:
[0029] a) 1 mole of nintedanib and 28-32 moles of propranolol;
[0030] b) 1 mole of propranolol and 4.5–5.5 moles of tranilast;
[0031] c) 1 mole of nintedanib and 38-42 moles of fosinopril;
[0032] d) 1 mole of fosinopril and 1.9-2.1 moles of tranilast;
[0033] e) 1 mole of verapamil and 1.2–1.4 moles of propranolol; or
[0034] f) 1 mole of verapamil and 0.06–0.07 moles of nintedanib.
[0035] Optionally, the active substances each have approximately the following molar ratios:
[0036] a) 1 mole of nintedanib and 30 moles of propranolol;
[0037] b) 1 mole of propranolol and 5 moles of tranilast;
[0038] c) 1 mole of nintedanib and 40 moles of fosinopril;
[0039] d) 1 mole of fosinopril and 2 moles of trinitrosulfate;
[0040] e) 1 mole of verapamil and 1.33 moles of propranolol; or
[0041] f) 1 mole of verapamil and 0.066 moles of nintedanib.
[0042] Optionally, the active substances are present in the following amounts by weight percent:
[0043] a) 0.01-2% nintedanib and 0.05-30% propranolol;
[0044] b) 0.05-3% propranolol and 0.5-30% tranilast;
[0045] c) 0.01-0.5% nintedanib and 0.4-20% fosinopril;
[0046] d) 0.1-8% fosinopril and 0.12-10% tranilast;
[0047] e) 0.065-6.5% verapamil and 0.05-5% propranolol; or
[0048] f) 0.12-24% verapamil and 0.01-2% nintedanib.
[0049] Optionally, the active substances are present in the following amounts by weight percent:
[0050] a) 0.05-2% nintedanib and 0.7-28% propranolol;
[0051] b) 0.1-2% propranolol and 1-20% tranilast;
[0052] c) 0.05-0.5% nintedanib and 2-20% fosinopril;
[0053] d) 0.5-5% fosinopril and 0.6-6% tranilast;
[0054] e) 1-4% verapamil and 2-4% propranolol; or
[0055] f) 1-10% verapamil and 0.5-1.2% nintedanib.
[0056] Optionally, the active substances are present in the following amounts by weight percent:
[0057] a) 0.1-1.52% nintedanib and 1.4-21% propranolol;
[0058] b) 0.5-1.5% propranolol and 5-15% tranilast;
[0059] c) 0.1-0.25% Nydanib and 4-10% Fosinopril;
[0060] d) 1-5% fosinopril and 1.2-6% tranilast;
[0061] e) 2-3% verapamil and 2-3% propranolol; or
[0062] f) 2-8% verapamil and 0.8-1% nintedanib.
[0063] Optionally, the drug is in the form of a topical wash, cream, or gel.
[0064] Optionally, the drug is administered at doses of approximately 0.5, 1, 1.5, or 2 fingertip units (FTUs) for a maximum of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 cm. 2 The application rate of scar surface area is used for skin scars.
[0065] Optionally, the skin scar includes keloid scars.
[0066] Optionally, the skin scar includes hypertrophic scars.
[0067] Optionally, the skin scar includes atrophic scars or acne scars.
[0068] The second aspect – its use in manufacturing
[0069] According to a second aspect, the present invention relates to the use of any of the following combinations of active substances in the manufacture of a medicament for treating skin scars:
[0070] a) Nydanibue and propranolol;
[0071] b) Propranolol and Tranisol;
[0072] c) Nydanib and Fossimpley;
[0073] d) Forsimpley and Trinister;
[0074] e) Verapamil and propranolol; or
[0075] f) Verapamil and Nidanibu.
[0076] Optionally, the active substance has the corresponding molar ratio and / or corresponding weight amount listed in any of the corresponding options of the first aspect of the invention described above.
[0077] Optionally, the drug is used for topical application or local injection.
[0078] Optionally, the drug is in the form of a topical wash, cream, ointment, or gel.
[0079] Optionally, the drug is administered at doses of approximately 0.5, 1, 1.5, or 2 fingertip units (FTUs) for a maximum of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 cm. 2 The application rate of scar surface area is used for skin scars.
[0080] Optionally, the skin scar includes keloid scars.
[0081] Optionally, the skin scar includes hypertrophic scars.
[0082] Optionally, the skin scar includes atrophic scars or acne scars.
[0083] The third aspect – treatment methods
[0084] According to a third aspect of the present invention, a method for treating skin scars in a human subject is provided, the method comprising applying a drug to the scar, the drug comprising any one of the following combinations of active substances:
[0085] a) Nydanibue and propranolol;
[0086] b) Propranolol and Tranisol;
[0087] c) Nydanib and Fossimpley;
[0088] d) Forsimpley and Trinister;
[0089] e) Verapamil and propranolol; or
[0090] f) Verapamil and Nidanibu.
[0091] Optionally, the drug has an amount of active substance in the corresponding molar ratio and / or corresponding weight as listed in any of the corresponding options of the first aspect of the invention described above.
[0092] Optionally, the drug may be applied topically to the scar surface or administered by local injection at or adjacent to the scar.
[0093] Optionally, the drug is in the form of a topical wash, cream, ointment, or gel.
[0094] Optionally, the drug is administered at doses of approximately 0.5, 1, 1.5, or 2 fingertip units (FTUs) for a maximum of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 cm. 2 The application rate of the scar surface area is applied to the scar.
[0095] Optionally, the skin scar includes keloid scars.
[0096] Optionally, the skin scar includes hypertrophic scars.
[0097] Optionally, the skin scar includes atrophic scars or acne scars. Attached Figure Description
[0098] Some preferred embodiments of the invention will now be described by way of examples and with reference to the accompanying drawings / figures, wherein -
[0099] Figure 1 This is a schematic diagram of the MTS assay results, which measures the ability of various active drugs to inhibit keloid cells.
[0100] Figure 2 This is a schematic diagram of the MTS assay results involving the propranolol + fosinopril combination to determine its ability to inhibit keloid cells;
[0101] Figure 3 This is a schematic diagram of the MTS assay results involving the combination of propranolol and tranilast to determine its ability to inhibit keloid cells;
[0102] Figure 4 This is a schematic diagram of the MTS assay results involving the combination of propranolol and nintedanib to determine its ability to inhibit keloid cells;
[0103] Figure 5 This is a schematic diagram of the MTS assay results involving the combination of fosinopril and tranilast to determine its ability to inhibit keloid cells;
[0104] Figure 6 This is a schematic diagram of the MTS assay results involving the combination of fosinopril and nintedanib to determine its ability to inhibit keloid cells;
[0105] Figure 7 This is a schematic diagram of MTS assay results involving the combination of tranilast and nintedanib to determine its ability to inhibit keloid cells;
[0106] Figure 8-9 It involves propranolol and nidanib ( Figure 8 ) and Forsimpley and Trinister ( Figure 9 A schematic diagram of the results of a combined assay of the combination of ) to determine its ability to inhibit keloid cells at different dose concentrations at the same ratio;
[0107] Figure 10-11 It involves propranolol and nidanib ( Figure 10 ) and Forsimpley & Trinister ( Figure 11 A schematic diagram of the results of MTS assays for the combination of ) to determine its ability to inhibit keloid cells at different dose concentrations at the same ratio;
[0108] Figure 12 This is a schematic diagram of the results of a wound closure assay involving the combination of fosinopril and tranilast to determine their ability to inhibit keloid cells and close wounds at different dose concentrations at the same ratio;
[0109] Figure 13 This is a diagram illustrating the ability of the combination of nintedanib and propranolol to inhibit fibroblasts in keloids;
[0110] Figure 14 This is a diagram illustrating the ability of the nintedanib + propranolol combination to affect the vitality of fibroblasts in keloids;
[0111] Figure 15 This is a diagram illustrating the ability of the verapamil + propranolol combination to inhibit fibroblasts in keloids;
[0112] Figure 16 This is a diagram illustrating the ability of the verapamil + propranolol combination to affect the vitality of fibroblasts in keloids;
[0113] Figure 17 This is a diagram illustrating the ability of the verapamil + nintedanib combination to inhibit fibroblasts in keloids;
[0114] Figure 18 This is a diagram illustrating the ability of the verapamil + nintedanib combination to affect the viability of fibroblasts in keloids;
[0115] Figure 19 This is a diagram illustrating the wound closure test results of the propranolol + nintedanib combination;
[0116] Figure 20 This is a diagram illustrating the wound closure test results of the verapamil + propranolol combination;
[0117] Figure 21 This is a diagram illustrating the wound closure test results of the verapamil + nintedanib combination;
[0118] Figure 22 It is a diagram illustrating the signal transduction pathway test results of various drugs and drug combinations; and
[0119] Figure 23 This is a diagram illustrating the test results of collagen production from various drugs and drug combinations. Detailed Implementation
[0120] Studies have been conducted using keloid scar tissue as a human disease model to develop treatments for skin scars, as described below.
[0121] Establishing primary cell lines from keloid tissue
[0122] Keloid tissue was digested using physical shearing and a mixture of type I collagenase, type II collagenase, and DNase. After incubation at 37°C for 3 hours, the digested tissue was filtered to remove debris, and red blood cells were lysed with cold RBC lysis buffer for 10 minutes. The product was passed through a filter again and centrifuged at 500×g for 5 minutes. The supernatant was removed, and the resulting pellet was resuspended in growth medium for cell counting using trypan blue. The digest was either frozen in cryopreservation medium (70% Advanced DMEM, 20% FBS, 10% DMSO) or immediately seeded in Kelch medium (3:1 DMEM:F12, 10% FBS, 1% AA, 20 ng / mL KGF, 10 uM ROCK inhibitor) for keratinocyte selection or in DMEM (10% FBS, 1% AA) for fibroblast selection.
[0123] Cell types were identified using optical microscopy and protein expression via immunofluorescence. Under optical microscopy, fibroblasts appeared as elongated, wavy structures as they grew to near confluence, while keratinocytes appeared as clusters of small pebbles. Cytokeratin 14 was used as a marker of proliferating keratinocytes; it was visible in keratinocytes but not in fibroblasts. Vimentin was used as a marker of fibroblasts; it was visible in fibroblasts but not in keratinocytes. Finally, cytokeratin 10 was used as a marker of differentiated keratinocytes, and it was found to be expressed at low levels in keratinocytes but absent in fibroblasts.
[0124] Cell lines tested with reagents
[0125] The following drugs were selected to test their ability to inhibit the above cell lines:
[0126] Tranilast, Pirfenidone, Sorafenib, Nintedanib, Metformin, Cromoglycate, Propranolol, Fosinopril, Fasudil, EMA401.
[0127] This assay included the use of the MTS assay as a measure of cell inhibition. Various concentrations of each drug were applied to keratinocytes and fibroblasts (n=3). These cells received daily doses of these drugs for three consecutive days. At the end of day three, the test medium was replaced with fresh basal medium containing the MTS reagent and cultured at 37°C for 2 hours. The absorbance of the test samples was measured at 490 nm using a spectrophotometer. For all values and the blank, the blank was subtracted, and the result was expressed as a fold change relative to the control. Reference Figure 1The most effective drugs against both cell lines were propranolol, fosinopril, nintedanib, sorafenib, WZB117, and tranilast. Propranolol, fosinopril, nintedanib, and tranilast were selected for further testing.
[0128] Cooperative interaction
[0129] The ability of propranolol, fosinopril, nintedanib, and tranilast to inhibit or suppress the cell lines prepared above was tested in various combinations. The MTS assay was used again.
[0130] More specifically, cells were treated with one drug at a concentration range and another drug at a concentration range. These cells received a single daily dose, and at the end of the third day, they underwent an MTS assay as described above. The test results were plotted as intensity maps to assess any synergistic interactions among the various combinations. Darker areas in each map represent regions of greatest synergy, and overlapping areas are used to measure the effectiveness of the combination.
[0131] All six combinations show some high and some low synergy scores, based on the concentration used. Referring to the figures mentioned below, which contain a grid (located on the right side of the page in each figure), areas of high synergy are highlighted in red.
[0132] Propranolol + Fosinopril
[0133] refer to Figure 2 The figure shows the results of propranolol + fosinopril (Prop + Fos) on fibroblasts (top) and keratinocytes (bottom). Fibroblasts showed a weak synergistic score, while keratinocytes showed a high synergistic score.
[0134] Collaborative Region:
[0135] • Fibroblasts: Prop: 40-60 µM Fos: 80-100 µM
[0136] • Keratinocytes: Prop: 40-60 µM Fos: 10-20 µM
[0137] Propranolol + Trinister
[0138] Figure 3 The results of propranolol + tranilast (Prop + Tran) on fibroblasts (top) and keratinocytes (bottom) are shown. Fibroblasts had low synergistic scores, while keratinocytes had high synergistic scores.
[0139] Collaborative Region:
[0140] • Fibroblasts: Prop: 20-60 µM Tran: 100-300 µM
[0141] • Keratinocytes: Prop: 40-60 µM Tran: 150-300 µM
[0142] Propranolol + Nydanib
[0143] Figure 4 The results of propranolol + nintedanib on fibroblasts (top) and keratinocytes (bottom) are shown. Fibroblasts showed good synergistic scores, while keratinocytes showed high synergistic scores.
[0144] Collaborative Region:
[0145] • Fibroblasts: Prop: 20-60 µM Nin: 1-2 µM
[0146] • Keratinocytes: Prop: 40-80 µM Nin: 1.25-2.5 µM
[0147] Fossimpley + Trinister
[0148] Figure 5 The results of fosinopril + tranexamic acid (Fos + Tran) on fibroblasts (top) and keratinocytes (bottom) are shown. Fibroblasts showed a high synergistic score, while keratinocytes showed a low synergistic score.
[0149] Collaborative Region:
[0150] • Fibroblasts: Fos: 80 µM Tran: 100-200 µM
[0151] • Keratinocytes: Fos: 10-20 µM Tran: 75-150 µM
[0152] Fossimpley + Nydanibu
[0153] Figure 6 The results of fosinopril + nintedanib (Fos + Nin) on fibroblasts (top panel) and keratinocytes (bottom panel) are shown. The synergistic score of fibroblasts was average, while the synergistic score of keratinocytes was low.
[0154] Collaborative Region:
[0155] • Fibroblasts: Fos: 80 µM Nin: 2-4 µM
[0156] • Keratinocytes: Fos: 10-20 µM Nin: 2-5 µM
[0157] Trinister and Nidanib
[0158] Figure 7 The results of tranilast and nintedanib (Tran + Nin) on fibroblasts (top panel) and keratinocytes (bottom panel) are shown. Both had low synergistic scores.
[0159] Collaborative Region:
[0160] • Fibroblasts: Tran: 100-200 µM Nin: 2-4 µM
[0161] • Keratinocytes: Tran: 75-150 µM Nin: 2-5 µM
[0162] The effectiveness of drug combinations with different concentration-ratios
[0163] Following screening, the following combinations were selected for further studies of the fibroblasts as described above, and were performed at different concentrations within each range at the following molar ratios:
[0164] •Prop :Nin 30:1
[0165] •Prop :Tran 1:5
[0166] •Fos :Nin 40:1
[0167] •Fos :Tran 1:2
[0168] For each cell sample, the daily dose of the drug combination was administered for 3 days in a manner similar to the administration described above. Other assays were performed, such as administering a single dose over 3 days.
[0169] Prop-Nin and nidanib
[0170] refer to Figure 8 The concentration range of propranolol and nintedanib at a drug ratio of 30:1 was tested. A synergistic effect was observed on growth curves at all concentrations of the combination, except at the high concentration of 90 µM: 3 µM triple dose, where the amount of drug administered alone was high enough to inhibit growth.
[0171] refer to Figure 9 This further illustrates the synergistic inhibitory effect observed at 30:1 µM and 60:2 µM doses for both the single-dose and three-dose models. While a single dose of 90:3 µM showed a synergistic effect, regardless of the synergistic effect, the amount of each individual drug was considered high enough to achieve inhibition.
[0172] Fos-Tran & Foss-Tran
[0173] refer to Figure 10 The results for the fosinopril & tranilast combination showed a synergistic effect at a single dose of 100:200 µM. And as... Figure 11 As shown, a synergistic effect for inhibition was observed at this concentration and dosing regimen. Furthermore, as... Figure 12 As shown, the synergistic effect of this combination was observed in the wound healing assay at 80:160 µM.
[0174] Further testing / comparison
[0175] A series of tests / comparisons were conducted to evaluate the ability of various drugs or combinations to inhibit the proliferation of keloid scar tissue.
[0176] For this purpose, primary cells were extracted from keloid tissue by physical cutting with scissors and then immersing the tissue in an enzyme digestion buffer solution containing 0.1% type I collagenase, 0.25% type II collagenase, 0.2 mg / ml DNase I, 1% FCS, and 1% antibiotic / antifungal agent in DMEM. The solution was mixed every 30 minutes and incubated at 37°C for 3 hours, then digestion was stopped by adding 1 ml of FCS. The sample was passed through a 100 µM filter, then through a 40 µM filter to remove debris, and subsequently incubated with cold erythrocyte lysis buffer for 10 minutes. After centrifugation at 500×g for 5 minutes, the resulting pellet was resuspended in cell type-specific growth medium for selection of keratinocytes (3:1 DMEM:F12, 10% FBS, 1% AA, 20 ng / mL KGF, 10 µM ROCK inhibitor) or fibroblasts (DMEM, 10% FBS, 1% AA).
[0177] Cell types were identified using optical microscopy and immunofluorescence. Under an optical microscope, fibroblasts appeared as wavy, elongated structures, while keratinocytes appeared as clusters of small pebbles. Cytokeratin 14 was used as a marker of proliferating keratinocytes; it was visible in cells grown in keratinocyte growth medium (KGM) but not observed in cells grown in fibroblast growth medium (FGM). Vimentin was used as a marker of fibroblasts; it was visible in cells grown in FGM but expressed at low levels in cells grown in KGM. Cytokeratin 10 was used as a marker of differentiated keratinocytes and was found to be expressed at low levels in cells grown in keratinocyte growth medium but absent in cells grown in fibroblast growth medium.
[0178] Primary cells were extracted from fresh keloid tissue to produce two main cell types, keratinocytes and fibroblasts, and their growth was selected using different growth medium formulations. KGM was based on Kelch medium with added growth factors necessary for keratinocyte proliferation while inhibiting fibroblast growth. FGM, used, is a common cell culture medium that proliferates fibroblasts but is insufficient on its own to promote keratinocyte growth. Cells were selected for high purity using each growth medium. Using this digestion method and growth medium, primary cells were identified as either keratinocytes or fibroblasts derived from keloids. The response of fibroblasts to various drugs was evaluated only, as described below.
[0179] The drug candidates in the table below were screened using an MTS assay to measure their inhibition of cell proliferation.
[0180]
[0181] In each case, the drug was prepared in ddH2O or dimethyl sulfoxide (DMSO) according to solubility and stored in aliquots at -80°C. A series of concentrations were tested in three different primary cell lines, with the mediator control matched to the highest dose (n=3). Cells received daily doses of the drug over 72 hours and were then exchanged for fresh medium containing MTS tetrazolium salt. They were cultured at 37°C for 2 hours to allow the MTS tetrazolium salt to be reduced to a colored formazan dye from live cells, and the optical density was measured at 490 nm using a spectrophotometer. Inhibition of cell proliferation was calculated using the following formula [1]:
[0182]
[0183] Inhibition of at least 50% of fibroblast proliferation in keloid scars was identified as an effective drug candidate for further investigation. Six of the fourteen tested drugs met this threshold:
[0184] 1. Trinister;
[0185] 2. Sorafenib;
[0186] 3. Nydanibu;
[0187] 4. Propranolol;
[0188] 5. Verapamil; and
[0189] 6. Fossimpson.
[0190] Except for tranilast, all six drugs achieved nearly 100% inhibition rates. Although tranilast did not achieve such high inhibition, it was selected for further research because it is currently used as a treatment in some countries.
[0191] Drug combination
[0192] Next, various combinations of these drugs were tested to discover possible synergistic interactions between them. This involved using the MTS assay to measure the inhibition of keloid fibroblast proliferation as the primary outcome. Cells were given daily doses of each combination over 72 hours at concentration ranges. Inhibition of cell proliferation was measured as previously described (see Equation [1]). More specifically, the test was repeated in three independent primary keloid-derived fibroblasts. Inhibition values were entered into SynergyFinder software (https: / / synergyfinder.fimm.fi / synergy / synfin_docs / #welcome) to display overlapping “most synergistic regions” used to determine the effectiveness of the tested combinations. The following table shows the drug combinations and concentrations and the results obtained.
[0193] surface
[0194]
[0195] Of the 10 drug combinations shown in the table above, the following combinations were selected for further testing (the following ratios are molar ratios):
[0196] • 30 propranolol + 1 nidanibue
[0197] • 1 propranolol + 5 trinitroglycerin
[0198] • 40 Forsimpson + 1 Nydanibu
[0199] • 1 Forsinolide + 2 Trinister
[0200] • 3 verapamil + 4 propranolol
[0201] • 15 Verapamil + 1 Nidanibu
[0202] These six drugs are administered either as a single dose over 72 hours or as three doses every 24 hours. In each case, the combination is compared to the individual drugs and a control. So, for example, the combination of propranolol + nintedanib is compared to propranolol alone, nintedanib alone, and a control.
[0203] Daily images of cells were captured using Incucyte (Sartorius), and keloid fibroblast proliferation was measured using analysis software. MTS assays were again used as the endpoint measurement of cell viability. Experiments were repeated using at least three independent primary keloid-derived fibroblast lines. Statistical analysis was performed using GraphPad Prism 9. Two-way ANOVA RM was performed on cell proliferation data at concentration and time. Two-way ANOVA was also performed on cell viability at drug / concentration. Post-hoc analysis was performed using the Dunnett method to correct for multiple comparisons of means against combination therapies, with a significance level of P < 0.05. Data are expressed as mean ± SEM.
[0204] Propranolol + Nydanib
[0205] More specifically, and refer to Figure 13 For the 30:1 propranolol + nintedanib combination, keloid-derived fibroblasts were treated with propranolol (red), nintedanib (blue), or propranolol + nintedanib combination (green) as a single or daily dose over 72 hours. Concentrations at a fixed ratio of 30:1 were tested: (AB) 30 µM : 1 µM, (CD) 60 µM : 2 µM, and (EF) 90 µM : 3 µM. Two-way ANOVA RM analysis was performed on the treatment and time of propranolol, nintedanib, and the combination. Significant differences between propranolol + nintedanib (combination) and propranolol alone (P < 0.05) were indicated by the symbol “*”, while significant differences between propranolol + nintedanib (combination) and nintedanib alone were indicated by “#”. Data are presented as mean ± SEM, with single-dose n = 3 and three-dose n = 5.
[0206] also, Figure 14 This study describes the cell viability of keloid-derived fibroblasts as determined by MTS after 72 hours of treatment with (A) a single dose or (B) a daily dose of propranolol (red), nintedanib (blue), or a combination of PropNin (green). Two-way ANOVA analysis was performed on the treatments and concentrations of propranolol, nintedanib, and the combination. Significant differences between the combination and propranolol alone (P < 0.05) were indicated by the symbol “*”, while significant differences between the combination and nintedanib alone (P < 0.05) were indicated by the symbol “#”. Data are presented as mean ± SEM, with single-dose n = 3 and three-dose n = 5.
[0207] Tests showed that the combination had a synergistic effect across all three concentration ranges in single-dose experiments.
[0208] Verapamil + Propranolol
[0209] Similar tests were conducted on the 3:4 verapamil + propranolol at low (15µM : 20µM), medium (30µM : 40µM), and high (45µM : 60µM) concentrations. For this combination, only daily dose experiments were performed.
[0210] The results are as follows Figure 15 and 16 As shown (combined as VP lines). A significant synergistic effect was observed at medium and high concentrations, inhibiting cell growth curves and cell viability.
[0211] Verapamil + Nidanibu
[0212] Similar tests were conducted on the 15:1 verapamil + nintedanib combination at low (15µM : 1µM), medium (30µM : 2µM), and high (45µM : 3µM) concentrations. For this combination, only daily dose experiments were performed.
[0213] The results are as follows Figure 17 and 18 As shown (combined as VP lines). A synergistic effect was observed at medium and high concentrations, inhibiting cell growth and cell viability.
[0214] Other drug combinations did not yield as good results as the three combinations mentioned above.
[0215] Cellular function and signal transduction pathways
[0216] The effects of the following drug combinations on fibroblast migration and protein expression in keloids were tested.
[0217] • 30 µM propranolol + 1 µM nintedanib
[0218] • 3 µM verapamil + 4 µM propranolol
[0219] • 15 µM Verapamil + 1 µM Nidanibue
[0220] A set of concentrations was selected from each combination to study protein signaling and collagen production. Based on the experiments described above, the concentrations used for measurement were chosen according to the lowest concentration at which a synergistic effect was observed.
[0221] Wound healing assay
[0222] In addition, for each combination, keloid fibroblasts were seeded into 96-well plates and grown to confluence before wounding using specialized wounding tools to ensure uniform wound size. Floating cells and culture medium were removed, and the cells were washed twice with PBS, then replaced with fresh DMEM and treated once with various drugs. Cell migration was monitored every 6 hours over 48 hours using Incucyte, and wound closure was measured using ImageJ. Two-way ANOVA RM statistical analysis was performed on the time-course data using GraphPad Prism 9. The area under the curve was measured using GraphPad Prism 9.
[0223] Protein blot
[0224] For each combination, keloid fibroblasts were seeded into 6-well plates and allowed to grow to confluence. Cells were washed twice with PBS and replaced with fresh DMEM, then incubated overnight. The following morning, cells were treated with 10 ng TGF-β and various drugs for 30 minutes. The culture medium was immediately removed, and cells were washed twice with cold PBS and incubated with Haltib-supplemented DMEM. TM The protease and phosphatase inhibitors were lysed using RIPA lysis buffer. Samples were collected in new microtubes and sonicated for 2 minutes, then centrifuged at 13,000 x g for 10 minutes at 4°C. The supernatant was collected, and protein concentration was determined using a Pierce BCA protein assay.
[0225] Samples for Western blotting were prepared by equilibrating all sample concentrations with 4X Bolt LDS buffer, 10X Bolt reducing agent, and water, and stored at -20°C. Samples were loaded onto Bolt Tris gels for SDS-PAGE and transferred to nitrocellulose membranes using a Power Blotter (Invitrogen). The membranes were blocked in TBST with 5% skim milk for 1 hour and incubated overnight at 4°C with the target primary antibody. The following morning, the membranes were incubated with their respective secondary antibody species for 1 hour and imaged with ECL chemiluminescence using a ChemiDoc (Bio-rad) scanner. The secondary antibody was peeled off the membranes, and the membranes were reprobeted with a different primary antibody. Density bands were measured using ImageJ. One-way ANOVA statistical analysis was then performed on the control and each drug combination group using GraphPad Prism 9.
[0226] ELISA
[0227] For each combination, keloid fibroblasts were seeded into 6-well plates and allowed to confluence. Cells were washed twice with PBS and replaced with fresh DMEM and the respective drugs. After 24 hours, the culture medium was collected and centrifuged at 300×g for 10 min at 4°C. Cells were washed twice with ice-cold PBS and proteins were extracted as described above. Both the culture medium and cell lysates were stored at -80°C until all samples were collected. Human Pro-Collagen 1 alpha 1 DuoSet ELISA (#DY6220-05, R&D Systems) was performed according to the manufacturer's instructions. The optimal sample dilutions were 1:100 (for culture medium) and 1:500 (for cell lysates). Statistical analysis was performed on the control and each drug combination groups using a GraphPad Prism 9.
[0228] Wound healing results
[0229] Reference wound closure analysis Figure 19 The study found that low and medium concentrations of propranolol combined with nintedanib had a synergistic effect in inhibiting cell migration.
[0230] refer to Figure 20 Wound closure analysis of the low-concentration verapamil + propranolol combination showed no significant difference compared to the control or either drug alone in terms of wound closure and total area. At medium concentrations, the combination was significantly different from verapamil alone at 24 and 36 hours, but showed no difference in total closure area. The high-concentration combination showed significant differences compared to either drug alone in terms of wound closure and total area over time. It is believed that the high-concentration combination exhibits a synergistic effect in inhibiting cell migration.
[0231] refer to Figure 21 In terms of wound closure analysis, all three concentrations of verapamil + nintedanib combination showed significant differences compared to the control and verapamil alone, but there were no significant differences in wound closure over time and total closure area compared to nintedanib alone.
[0232] Signal transduction pathway assessment
[0233] Due to the role of drug combinations in wound healing and scar formation in both normal tissue and keloids, their effects on signaling pathways such as MAPK and the TGFβ / Smad pathway were evaluated. Phosphorylation of ERK1 / 2 and Smad2 was measured, as they are key targets in their respective pathways. In these assays, exogenous TGFβ required stimulation of Smad phosphorylation but not ERK1 / 2 phosphorylation. Therefore, keloid fibroblasts were treated simultaneously with TGFβ and the drugs, as the same sample was used to probe both pathways. Results showed... Figure 22 middle.
[0234] As stated above, the propranolol + nintedanib combination reduced ERK1 and ERK2 phosphorylation compared to the TGF+ control and propranolol alone. This effect appears to be primarily driven by nintedanib, as the phosphorylation of the combination was not different from that of nintedanib alone, suggesting that the reduction in signal was mainly driven by nintedanib.
[0235] Compared with TGF+ control and verapamil alone, the verapamil + nintedanib combination resulted in reduced phosphorylation levels of ERK1, ERK2, and Smad2. This effect appears to be primarily driven by nintedanib, as there was no difference in phosphorylation between VerNin and nintedanib.
[0236] There were no significant differences in the phosphorylation of ERK1, ERK2, and Smad2 in the verapamil + propranolol combination.
[0237] The effect of drug combination on collagen production
[0238] One characteristic of the pathogenesis of keloids is the increased production of type I and type III collagen. Therefore, an ideal combination of drugs is needed to inhibit this effect. The effect of this drug combination on human procollagen 1A1 was determined using an ELISA kit. Results showed... Figure 23 middle.
[0239] As shown in the figure, the concentration of COL1A1 in the cell culture medium after drug treatment did not differ significantly, indicating that it had almost no effect on collagen secretion.
[0240] After treatment with propranolol (30 µM) and nintedanib (1 µM) alone, there was no significant difference in COL1A1 concentration in keloid fibroblasts compared to the control. However, the PropNin combination showed a significant reduction in COL1A1, although this combination was not significantly different from propranolol or nintedanib alone. This suggests that a synergistic interaction is at play.
[0241] The concentration of COL1A1 in cells treated with a combination of verapamil, propranolol (40 µM), and VerProp was significantly different from the control. However, the VerProp combination did not show a significant difference compared to verapamil or propranolol alone.
[0242] Compared with the control, there was no significant difference in COL1A1 concentration in cells after nintedanib (2µM) treatment. The VerNin combination showed a significant difference compared with the control, but no significant difference compared with verapamil or nintedanib alone.
[0243] Overall, wound healing assays showed that the PropNin combination produced the most significant synergistic effect among the three drug combinations. The VerProp combination also showed a synergistic effect at the highest concentration. Furthermore, the VerNin combination exhibited the greatest inhibition of signal transduction pathways, followed by PropNin. All three combinations showed a reduction in cellular COL1A1, indicating that all combinations are effective in reducing collagen synthesis. In summary, the PropNin combination appears to have shown the most significant effect across all assays, surprisingly demonstrating a significant impact on multiple aspects of skin scar formation and healing.
[0244] While some forms of the invention have been described by way of examples, it should be understood that modifications and improvements may be made without departing from the scope of the appended claims.
[0245] In its disclosure, this document contemplates and thereby presupposes any feature mentioned herein combined with its own repetition (e.g., two identical ones) and / or any other feature mentioned herein, even if such combination is not claimed in the appended claims.
Claims
1. A medicine for treating skin scars, comprising a combination of nintedanib and propranolol.
2. The medicament according to claim 1, used for local treatment or local injection at or near the scar.
3. The medicament according to claim 1 or 2, wherein the ratio of the active substance is 1 mole of nintedanib and 27-33 moles of propranolol.
4. The medicament according to claim 1 or 2, wherein the ratio of the active substance is 1 mole of nintedanib and 28-32 moles of propranolol.
5. The medicament according to claim 1 or 2, wherein the ratio of the active substances is 1 mole of nintedanib and 30 moles of propranolol.
6. The medicament according to any one of the preceding claims, wherein the active substances are 0.01-2% nintedanib and 0.05-30% propranolol in weight percent.
7. The medicament according to any one of the preceding claims, wherein it is in the form of a topical lotion, cream, ointment or gel.
8. The medicament according to any one of the preceding claims, wherein the dosage is approximately 0.5, 1, 1.5, or 2 fingertip units (FTU) for a maximum of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 cm. 2 The application rate of scar surface area is used for skin scars.
9. The medicament according to any one of the preceding claims, wherein the skin scar comprises a keloid scar.
10. The medicament according to any one of claims 1-8, wherein the skin scar comprises a hypertrophic scar.
11. The medicament according to any one of claims 1-8, wherein the skin scar comprises atrophic scar or acne scar.
12. Use of the combination of nintedanib and propranolol in the preparation of a medicament for the treatment of skin scars.
13. The use according to claim 12, wherein the drug has an amount of active substance in the corresponding molar ratio and / or corresponding weight as described in any one of claims 3-6.
14. The use according to claim 12 or 13, wherein the drug is for topical application or local injection.
15. The use according to claim 12 or 13, wherein the drug is in the form of a topical wash, cream, ointment or gel.
16. The use according to any one of claims 12-15, wherein the drug is administered at a dose of approximately 0.5, 1, 1.5, or 2 fingertip units (FTU) for a maximum of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 cm. 2 The application rate of scar surface area is used for skin scars.
17. The use according to any one of claims 12-16, wherein the skin scar comprises a keloid scar.
18. The use according to any one of claims 12-16, wherein the skin scar comprises a hypertrophic scar.
19. The use according to any one of claims 12-16, wherein the skin scar comprises atrophic scars or acne scars.
20. A method for treating skin scars in a human subject, comprising applying a drug comprising nintedanib and propranolol to the scar.
21. The method according to claim 20, wherein the drug has an amount of active substance in the corresponding molar ratio and / or corresponding weight as described in any one of claims 3-6.
22. The method of claim 20 or 21, wherein the drug is applied topically to the scar surface or administered by local injection at or adjacent to the scar.
23. The method according to claim 20 or 21, wherein the drug is in the form of a topical wash, cream, ointment or gel.
24. The method according to any one of claims 20-23, wherein the drug is administered at approximately 0.5, 1, 1.5, or 2 fingertip units (FTU) for a maximum of approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 cm. 2 The application rate of the scar surface area is applied to the scar.
25. The method according to any one of claims 20-24, wherein the skin scar comprises a keloid scar.
26. The method according to any one of claims 20-24, wherein the skin scar comprises a hypertrophic scar.
27. The method according to any one of claims 20-24, wherein the skin scar comprises atrophic scar or acne scar.
